Drugs / Epothilone D
Epothilone D
also known as
Utidelone · UTD1 · KOS-862 · UTD2 · (-)-desoxyepothilone b · 12,13-desoxyepothilone b · 12,13-desoxyepothilone b, cis · NSC-703147 · +3 more
Trials 45 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05681000 | Jun 2023 → Apr 2024 | — | Biostar Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05700084 | Jun 2023 → Oct 2025 overdue | — | Beijing Biostar Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05052437 | Oct 2020 → Jan 2021 | breast cancer | Beijing Biostar Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00030173 | Oct 2001 → Jun 2003 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05535413 | Jan 2023 → Oct 2024 overdue | Her2-receptor negative breast cancer, metastatic malignant neoplasm in the brain | Hunan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00337649 | May 2004 → Jul 2007 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 229 trials | ||||||
| Phase 2 | NCT07449481 | May 2026 → Feb 2028 | metastatic malignant neoplasm in the brain | Tianjin Medical University Cancer Institute and Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06889610 | Mar 2026 → Dec 2027 expected | colorectal cancer, melanoma, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07363330 | Feb 2026 → Dec 2027 expected | cervical cancer | Zhongnan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07044349 | Sep 2025 → Mar 2027 expected | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06764940 | Jul 2025 → Jan 2027 expected | Her2-receptor negative breast cancer | Biostar Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06973421 | Jul 2025 → Jun 2027 expected | refractory malignant neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06683703 | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06730581 | Dec 2024 → Dec 2026 expected | bile duct cancer, gastric adenocarcinoma, ovarian cancer | Beijing Biostar Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06510465 | Aug 2024 → Mar 2027 expected | breast cancer | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06598046 | Jun 2024 → Jun 2026 overdue | breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06458413 | Jun 2024 → Jun 2025 | female breast carcinoma | Min Yan, MD | Unknown | No outcome recorded |
| Phase 2 | NCT06385990 | Mar 2024 → Mar 2025 overdue | triple-negative breast carcinoma | Hunan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06125080 | Oct 2023 → Oct 2025 overdue | triple-negative breast carcinoma | Huihua Xiong | Recruiting | No outcome recorded |
| Phase 2 | NCT05983094 | Sep 2023 → Sep 2026 expected | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05895864 | Jun 2023 → Dec 2024 | urothelial carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05866510 | May 2023 → Apr 2024 | esophageal cancer | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT05795920 | Mar 2023 → Jul 2024 | pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT05398861 | Aug 2022 → Dec 2026 expected | Her2-receptor negative breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05403333 | Jun 2022 → Mar 2023 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05357417 | Apr 2022 → May 2024 | breast cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05299255 | Sep 2021 → Sep 2022 | small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04681287 | Apr → Nov 2021 | HER2 positive breast carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04911907 | Jan 2021 → May 2025 | cancer | Beijing Biostar Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03693547 | Apr 2019 → Jun 2021 | non-small cell lung carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03906565 | Apr 2019 → Dec 2023 | colorectal cancer | Beijing Biostar Pharmaceuticals Co., Ltd. | Suspended | No outcome recorded |
| Phase 2 | NCT00104130 | Dec 2004 → Feb 2005 | prostate cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00080509 | Dec 2003 → Nov 2004 | lung cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00081107 | Dec 2003 → Dec 2004 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00077259 | Oct 2003 → Sep 2004 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06841679 | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07684456 | Aug 2026 → Mar 2028 expected | Her2-receptor negative breast cancer | Beijing Biostar Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07088263 | Sep 2025 → Jul 2027 expected | breast neoplasm | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07021261 | Jun 2025 → Jun 2030 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05954442 | Sep 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05673629 | May 2023 → Jun 2025 | breast cancer | Beijing Biostar Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05673590 | May 2023 → Jun 2025 | non-small cell lung carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05430399 | Jun 2022 → Jun 2025 overdue | Her2-receptor negative breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05172518 | Mar 2022 → Mar 2027 expected | breast cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02253459 | Aug 2014 → Sep 2016 | female breast carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT06678048 Background | Oct 2024 → Apr 2026 overdue | breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06102824 Comparator | Oct 2024 → Jun 2027 expected | Her2-receptor negative breast cancer | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06355037 Background | May → Dec 2024 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06355024 Background | May 2024 → Jan 2025 | triple-negative breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05806060 Comparator | Apr 2023 → May 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epothilone D | “The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer...” NCT00080509 ↗5“Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer” NCT00104130 ↗ |
| Known as | (-)-desoxyepothilone b | ChEMBL registry synonym — accepted as the source's own label CHEMBL96172 ↗ |
| Known as | 12,13-desoxyepothilone b | ChEMBL registry synonym — accepted as the source's own label CHEMBL96172 ↗ |
| Known as | 12,13-desoxyepothilone b, cis | ChEMBL registry synonym — accepted as the source's own label CHEMBL96172 ↗ |
| Known as | KOS-862 | “A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic...” NCT00077259 ↗ |
| Known as | NSC-703147 | ChEMBL registry synonym — accepted as the source's own label CHEMBL96172 ↗ |
| Known as | R-1492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL96172 ↗ |
| Known as | UTD1 | “A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases” NCT06764940 ↗8“Utidelone (UTD1) is an epothilone derivative with a similar mechanism of action to taxanes, but a completely different molecular structure.” NCT05299255 ↗ “Multimodal ablation combined with pucotenlimab and TPC or sacituzumab govitecan, eribulin,gemcitabine,UTD1” NCT06889610 ↗ “UTD1 30mg/m2 d1-5 ivgtt, every 3 weeks” NCT05806060 ↗ |
| Known as | UTD2 | “Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer” NCT07044349 ↗1“Patients who met the enrollment criteria received Utidelone capsule (UTD2) monotherapy.” NCT06730581 ↗ |
| Known as | Utidelone | “This study evaluated the efficacy and safety of a novel, fully China-developed combination therapy-comprising inetetamab (an anti-HER2 monoclonal antibody), camrelizumab (an...” PMID 41593669 ↗ Jan 202636“The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone)...” NCT05954442 ↗ “Palliative chemotherapy regimen includes Eribulin, Gemcitabine, Utidelone and Vinorelbine, by the treatment of physician's choice (TPC).” NCT06678048 ↗ |
| Known as | Utidelone Capsule | “Utidelone Capsule: 60 mg/m2/d, administered once a day orally continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.” NCT07684456 ↗ |
| Known as | Utidelone Injection | “Utidelone Injection：30 mg/m2/d, administered once a day intravenously, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.” NCT07684456 ↗ |
| Action | Inhibit | “ability to initiate cell death by inhibiting such processes” NCT00030173 ↗ |
| Modality | Small molecule | “Epothilone D represents one of a class of cytotoxic macrolides capable of causing mitotic arrest by stabilizing tubulin polymerization.” NCT00030173 ↗ |
| Route | Intravenous | “Patients receive epothilone D IV over 90 minutes on days 1, 8, and 15.” NCT00077259 ↗ |